An Update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics

International Journal of Infectious Diseases

Volumn 30, Issue , 2015, Pages 125-132

  Kassamali, Zahra ^a   Jain, Rupali ^b   Danziger, Larry H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Acinetobacter infections drug therapy; Anti bacterial Agents administration dosage; Colistin administration dosage; Polymyxins pharmacology; Polymyxins therapeutic use

Indexed keywords

CARBAPENEM; COLISTIMETHATE; COLISTIN; IMIPENEM; MEROPENEM; POLYMYXIN B; RIFAMPICIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL CLEARANCE; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG USE; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PATIENT CARE; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ACINETOBACTER INFECTIONS; DRUG COMBINATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; POLYMYXIN B;

EID: 84918556534     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.10.014     Document Type: Review

References (90)

1. Jain R., Danziger L.H. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004, 38(9):1449-1459.
2. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29(11):996-1011.
3. Lee Y.T., Kuo S.C., Yang S.P., Lin Y.T., Tseng F.C., Chen T.L., et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 2012, 55(2):209-215.
4. Chen H.P., Chen T.L., Lai C.H., Fung C.P., Wong W.W., Yu K.W., et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005, 38(2):127-136.
5. Garnacho-Montero J., Ortiz-Leyba C., Jiménez-Jiménez F.J., Barrero-Almodovar A.E., Garcia-Garmendia J.L., Bernabeu-Wittell M., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36(9):1111-1118.
6. Grupper M., Sprecher H., Mashiach T., Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007, 28(3):293-298.
7. Karagoergopoulos D.E., Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008, 8:751-762.
8. Tygacil (tigecycline):Drug safety communication - Increased risk of death. Rockville, MD: MedWatch the FDA Safety Information and Adverse Event Reporting Program, U.S. Food and Drug Administration. 2013. (Accessed 2014 Mar 31). http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm370170.htm.
9. Landman D., Georgescu C., Martin D.A., Quale J. Polymyxins revisited. Clin Microbiol Rev 2008, 21(3):449-465.
10. Kassamali Z., Rotschafer J.C., Jones R.N., Prince R.A., Danziger L.H. Polymyxins: wisdom does not always come with age. Clin Infect Dis 2013, 57(6):877-883.
11. Fournier P.E., Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006, 42(5):692-699.
12. Rinder H. Hetero-resistance: an under-recognised confounder in diagnosis and therapy?. J Med Microbiol 2001, 50:1018-1020.
13. Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006, 50:2946-2959.
14. Hawley J.S., Murray C.K., Jorgensen J.H. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008, 52:351-352.
15. Tan C., Li J., Nation R.L. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother 2007, 51:3413-3415.
16. Garonzik S.M., Li J., Thamlikitkul V., Paterson D.L., Shoham S., Jacob J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55(7):3284-3294.
17. Sandri A.M., Landersdorfer C.B., Jacob J., Boniatti M.M., Dalarosa M.G., Falci D.R., et al. Population pharmacokinetics of polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clin Infect Dis 2013, 57(4):524-531.
18. Li J., Nation R.L., Turnridge J.D. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 2006, 50(6):2274-2275.
19. Falagas M., Kasiakou S. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother 2006, 50(6):2274-2275.
20. Goodwin N.J. Colistin sulfate versus sodium colistimethate. Ann Intern Med 1969, 70:232-233.
21. Sobieszcyzk M.E., Furuya E.Y., Hay C.M., Pancholi P., Della-Latta P., Hammer S.M., et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004, 54:566-569.
22. Product Information. Polymyxin B. Schaumburg, IL: Sagent Pharmaceuticals, 2011.
23. Brownlee G., Bushby S.R.M., Short E.I. The chemotherapy and pharmacology of the polymyxins. Brit J Pharmacol 1952, 7:170-188.
24. Ratjen F., Rietschel E., Kasel D., Schwiertz R., Starke K., Beier H., et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006, 57:306-311.
25. Zavascki A.P., Goldani L.Z., Cao G., Superti S.V., Lutz L., Barth A.L., et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008, 47:1298-1304.
26. Couet W., Gregoire N., Gobin P., Saulnier P.J., Frasca D., Marchand S., et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011, 89(6):875-879.
27. Abdelraouf A., He K., Ledesma K.R., Hu M., Tam V.H. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 2012, 56(11):5724-5727.
28. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004, 53:837-840.
29. Markantonis S.L., Markou N., Fousteri M., Sakellaridis N., Karatzas S., Alamano I., et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009, 53(11):4907-4910.
30. Imberti R., Cusato M., Accetta G., Marino V., Procaccio F., Del Gaudio A., et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanefulfonate. Antimicrob Agents Chemother 2012, 6(8):4416-4421.
31. Segal-Maurer S., Mariano N., Qavi A., Urban C., Rahal J.J. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: Case report and review. Clin Infect Dis 1999, 28:1134-1138.
32. Dalfino L., Puntillo F., Mosca A., Monno R., Spada M.L., Coppolecchia S., et al. High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy?. A preliminary study. Clin Infect Dis 2012, 54:1720-1729.
33. Sandri A.M., Landersdorfer C.B., Jacob J., Boniatti M.M., Dalarosa M.G., Falci D.R., et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 2013, 68:674-677.
34. Plachouras D., Karvanen M., Friberg L.E., Papadomichelakis E., Antoniadou A., Tsangaris I., et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009, 53(8):3430-3436.
35. Dudhani R.V., Turnidge J.D., Nation R.L., Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010, 65:1984-1990.
36. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
37. Hindler J.A., Humphries R.M. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant gram-negative bacilli. J Clin Microbiol 2013, 51(6):1678-1684.
38. Gales A.C., Reis A.O., Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Micro 2001, 39(1):183-190.
39. Falagas M.E., Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10(1):R27.
40. Phe K., Lee Y., McDaneld P.M., Prasad N., Yin T., Figueroa D.A., et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014, 58(5):2740-2746.
41. Suzuki T., Yamaguchi H., Ogura J., Kobayashi M., Yamada T., Iseki K. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 2013, 57(12):6319-6324.
42. Yousef J.M., Chen G., Hill P.A., Nation R.L., Li J. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011, 55(9):4044-4049.
43. Tuon F.F., Rigatto M.H., Lopes C.K., Kamei L.K., Rocha J.L., Zavascki A.P. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014, 43(4):349-352.
44. Hartzell J.D., Neff R., Ake J., Howard R., Olson S., Paolino K., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48(12):1724-1728.
45. Betrosian A.P., Frantzeskaki F., Xanthaki A., Douzinas E.E. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008, 56:432-436.
46. Kallel H., Hergafi L., Bahloul M., Hakim A., Dammak H., Chelly H. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007, 33:1162-1167.
47. Aydemir H., Akduman D., Piskin N., Comert F., Horuz E., Terzi A., et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013, 141:1214-1222.
48. Durante-Mangoni E., Signoriello G., Andini R., Mattei A., De Cristoforo M., Murino P., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013, 57(3):349-358.
49. Motaouakkil S., Charra B., Hachimi A., Nejmi H., Benslama A., Elmdaghri N., et al. Colistin and rifampicin in the treatment of nosocomial infection from multiresistant Acinetobacter baumannii. J Infect 2006, 53(4):274-278.
50. Bassetti M., Repetto E., Righi E., Boni S., Diverio M., Molinari M.P., et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008, 61(2):417-420.
51. Song J.Y., Lee J., Heo J.Y., Noh J.Y., Kim W.J., Cheong H.J., et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agent 2008, 32(3):281-284.
52. Petrosillo N., Chinello P., Proietti M.F., Cecchini L., Masala M., Franchi C., et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005, 11(8):682-683.
53. Pogue J.M., Lee J., Marchaim D., Yee V., Zhao J.J., Chopra T., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011, 53(9):879-884.
54. Product Information. Colymycin M (colistmethate) injection. Rochester, MN: JHP Pharmaceuticals, 2011.
55. Paul M., Bishara J., Levcovich A., Chowers M., Goldberg E., Singer P., et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010, 65(5):1019-1027.
56. Kvitko C.H., Rigatto M.H., Moro A.L., Zavascki A.P. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 2011, 66(1):175-179.
57. Kollef K.E., Schramm G.E., Wills A.R., Reichley R.M., Micek S.T., Kollef M.H. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008, 134:281-287.
58. Fagon J.Y., Chastre J., Domart Y., Trouillet J.L., Gibert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996, 23(3):538-542.
59. Dubrovskaya Y., Chen T., Scipione M.R., Esaian D., Phillips M.S., Papadopoulos, et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2013, 57(11):5394-5397.
60. Batirel A., Balkan I.I., Karabay O., Agalar C., Akalin S., Alici O., et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014, 33(8):1311-1322.
61. Song J.Y., Cheong H.J., Lee J., Sung A.K., Kim W.J. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 2009, 33(1):33-39.
62. Lee H.J., Bergen P.J., Bulitta J.B., Tsuji B., Forrest A., Nation R.L., et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother 2013, 57(8):3738-3745.
63. Falagas M.E., Rafailidis P.I., Ioannidou E., Alexiou V.G., Matthaiou D.K., Karageorgopoulos D.E., et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010, 35:194-199.
64. Simsek F., Gedik H., Yilirmak M.T., Iris N.E., Turkmen A., Ersoy A., et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy?. Indian J Med Microbiol 2012, 30(4):448-452.
65. Kaye K. Trial for the treatment of extensively drug-resistant Gram-negative bacilli. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2014 Mar 31]. Available from: NLM Identifier: . ctgov:NCT01597973.
66. Paul M; European Commission. Multicenter open-label randomized controlled trial (RCT) to compare colistin alone versus colistin plus meropenem. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2014 Mar 31]. Available from: NLM Identifier: . ctgov:NCT01732250.
67. Ouderkirk J.P., Nord J.A., Turrett G.S., Kislak J.W. Polymyxin B nephrotoxicity and efficacy and nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003, 47:2659-2662.
68. Pastewski A.A., Caruso P., Parris A.R., Dizon R., Kopec R., Sharma S., et al. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: A retrospective case series. Ann Pharmacother 2008, 42:1177-1187.
69. Crusio R., Rao S., Changawala N., Paul V., Tiu C., van Ginkel J., et al. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scand J Infect Dis 2014, 46(1):1-8.
70. Cai Y., Chai D., Wang R., Liang B., Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012, 67(7):1607-1615.
71. Imberti R., Cusato M., Villiani P., Carnevale L., Lotti G.A., Langer M., et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate adminstration. Chest 2010, 138(6):1333-1339.
72. Athanassa Z.E., Markantonis S.L., Fousteri M.Z., Myrianthefs P.M., Boutzouka E.G., Tsakris A., et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 2012, 38(11):1779-1786.
73. Kuo S.C., Lee Y.T., Yang S.P., Chen C.P., Chen T.L., Hsieh S.L., et al. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study. Clin Microbiol Infect 2012, 18:870-876.
74. Arnold H.M., Sawyer A.M., Kollef M.H. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 2012, 57(8):1226-1233.
75. Kalin G., Alp E., Coskun R., Demiraslan H., Gundogan K., Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?. J Infect Chemother 2012, 18(6):872-877.
76. Pereira G.H., Muller P.R., Levin A.S. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007, 58(2):235-240.
77. Michalopoulos A., Fotakis D., Virtzili S., Vletsas C., Raftopoulou S., Mastora Z., et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008, 102:407-412.
78. Information for Healthcare Professionals: Colistimethate (marketed as Coly-Mycin M and generic products). Rockville, MD: U.S. Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers, 28 June 2007. (accessed 2014 March 25). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm.
79. Korbila P., Michalopoulos A., Rafailidis P.K., Nikita D., Samonis G., Falagas M.E. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010, 16(8):1230-1236.
80. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002, 46(10):3304-3307.
81. Karvanen M., Plachouras D., Friberg L.E., Paramythiotou E., Papadomichelakis, Karaiskos I., et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2013, 57(1):668-671.
82. Cao G., Ali F.E., Zavascki A.P., Nation R.L., Li J. Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother 2008, 62(5):1009-1014.
83. Kumar A., Roberts D., Wood K., Light B., Parrillo J.E., Sharma S., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
84. Elias L.S., Konzen D., Krebs J.M., Zavascki A.P. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010, 65:2231-2237.
85. Gauthier T.P., Wolowich W.R., Reddy A., Cano E., Abbo L., Smith L.B. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012, 56(5):2392-2396.
86. Pai M.P., Polymyxin B. dosing in obese and underweight adults. Clin Infect Dis 2013, 57(12):1785.
87. Markou N., Fousteri M., Markantonis S.L., Zidianakis B., Hroni D., Boutzouka E., et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012, 67:2459-2462.
88. Tan Tock Seng Hospital. Randomized-controlled trial (RCT) on combination antibiotic for infections caused by Gram-negative bacteria (XDR-GNB). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2014 Oct 1]. Available from: NLM Identifier: . ctgov:NCT02134106.
89. Shaare Zedek Medical Center. Renal impairment associated with colistin levels. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2014 Oct 1]. Available from: NLM Identifier: . ctgov:NCT01023087.
90. Parc de Salut Mar. Multicentric study about the usefulness of monitoring plasma levels of colistin and sodium colistimethate in patients with infections due to multi-drug resistant Gram negative bacilli, treated with colistin. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2014 Oct 1]. Available from: NLM Identifier: . ctgov:NCT01845246.